Estrogen Receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 729-734

  Iwamoto, Takayuki ^a,b   Booser, Daniel ^a   Valero, Vicente ^a   Murray, James L ^a   Koenig, Kimberly ^a   Esteva, Francisco J ^a   Ueno, Naoto T ^a   Zhang, Jie ^a   Shi, Weiwei ^a   Qi, Yuan ^a   Matsuoka, Junji ^b   Yang, Elliana J ^a   Hortobagyi, Gabriel N ^a   Hatzis, Christos ^c   Symmans, W Fraser ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c Nuvera Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; ESR1 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, MESSENGER;

EID: 84863116462     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.2574     Document Type: Article

References (22)

1. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
2. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000 (Pubitemid 30185917)
3. Thomson CS, Twelves CJ, Mallon EA, et al: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11:419-429, 2002 (Pubitemid 35469501)
4. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581, 2006 (Pubitemid 44680908)
5. Phillips T, Murray G, Wakamiya K, et al: Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 15:325-331, 2007 (Pubitemid 47329926)
6. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007 (Pubitemid 47477259)
7. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
8. Viale G, Regan MM, Maiorano E, et al: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26:1404- 1410, 2008
9. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
10. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
11. Pusztai L, Ayers M, Stec J, et al: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogenpositive tumors. Clin Cancer Res 9:2406-2415, 2003 (Pubitemid 36842079)
12. Gruvberger S, Ringnér M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001 (Pubitemid 32762524)
13. Symmans WF, Hatzis C, Sotiriou C, et al: Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4111-4119, 2010
14. Badve SS, Baehner FL, Gray RP, et al: Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
15. Gong Y, Yan K, Lin F, et al: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: A gene-expression profiling study. Lancet Oncol 8:203-211, 2007
16. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
17. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006 (Pubitemid 46630780)
18. Popovici V, Chen W, Gallas BG, et al: Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12:R5, 2010
19. Tabchy A, Valero V, Vidaurre T, et al: Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16:5351-5361, 2010
20. Bianchini G, Iwamoto T, Qi Y, et al: Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 70:8852-8862, 2010
21. Allred DC, Carlson RW, Berry DA, et al: NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 7:S1-S21, 2009 (suppl 6)
22. Li Q, Eklund AC, Juul N, et al: Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One 5:e15031, 2010